Effect of Neoadjuvant Chemotherapy on MRI Accuracy Before Cystectomy
ConditionMuscle Invasive Bladder Cancer
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorAssiut University
About this trial
The goal of this clinical trial is to learn if neoadjuvant chemotherapy (NAC) affects the accuracy of magnetic resonance imaging (MRI) in staging muscle-invasive bladder cancer (MIBC). This study will also assess how tissue changes induced by NAC impact MRI interpretation. The main questions it aims to answer are:
Does NAC compromise the accuracy of MRI in staging MIBC?
Does NAC-induced tissue change affect the reliability of MRI in tumor assessment?
Researchers will compare MRI staging accuracy in MIBC patients who received NAC to those who went directly to surgery, to see if NAC impacts MRI's diagnostic performance.
Participants will:
Undergo MRI scanning before surgery
Receive either NAC or go directly to surgery, depending on their group assignment
Have their MRI results compared to histopathological outcomes after surgery
Eligibility criteria
Qualifiers
Patients diagnosed with cT2 urothelial carcinoma of the urinary bladder, according to the TNM classification, who give informed, written consent on participation in the study and approve all its requirements.
Disqualifiers
Patients who have received pelvic radiotherapy.
Previous open or laparoscopic pelvic surgery.
Patients with contraindications to MRI.
Patients who are unfit for or refuse radical cystectomy.
Trial design
Treatments tested in this trial
- Neoadjuvant Chemotherapy
- Radical Cystectomy
Treatment groups
76 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov